Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1136/bmjnph-2021-000269 http://scihub22266oqcxt.onion/10.1136/bmjnph-2021-000269 34308137!8214987!34308137     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       BMJ+Nutr+Prev+Health 2021 ; 4 (1): 285-292 Nephropedia Template TP {{tp|p=34308137|t=2021. Impact of smoking on COVID-19 outcomes: a HOPE Registry subanalysis |pdf=|usr=}}{{34308137}} gab.com Text Impact of smoking on COVID-19 outcomes: a HOPE Registry subanalysis JO: BMJ Nutr Prev Health http://www.kidney.de/pget.php?&tw=1&pmid=34308137 #FOAvip BACKGROUND: Smoking has been associated with poorer outcomes in relation to COVID-19. Smokers have higher risk of mortality and have a more severe clinical course. There is paucity of data available on this issue, and a definitive link between smoking and COVID-19 prognosis has yet to be established. METHODS: We included 5224 patients with COVID-19 with an available smoking history in a multicentre international registry Health Outcome Predictive Evaluation for COVID-19 (NCT04334291). Patients were included following an in-hospital admission with a COVID-19 diagnosis. We analysed the outcomes of patients with a current or prior history of smoking compared with the non-smoking group. The primary endpoint was all-cause in-hospital death. RESULTS: Finally, 5224 patients with COVID-19 with available smoking status were analysed. A total of 3983 (67.9%) patients were non-smokers, 934 (15.9%) were former smokers and 307 (5.2%) were active smokers. The median age was 66 years (IQR 52.0-77.0) and 58.6% were male. The most frequent comorbidities were hypertension (48.5%) and dyslipidaemia (33.0%). A relevant lung disease was present in 19.4%. In-hospital complications such sepsis (23.6%) and embolic events (4.3%) occurred more frequently in the smoker group (p<0.001 for both). All cause-death was higher among smokers (active or former smokers) compared with non-smokers (27.6 vs 18.4%, p<0.001). Following a multivariate analysis, current smoking was considered as an independent predictor of mortality (OR 1.77, 95% CI 1.11 to 2.82, p=0.017) and a combined endpoint of severe disease (OR 1.68, 95% CI 1.16 to 2.43, p=0.006). CONCLUSION: Smoking has a negative prognostic impact on patients hospitalised with COVID-19. Twit Text FOAVip Impact of smoking on COVID-19 outcomes: a HOPE Registry subanalysis ????BMJ Nutr Prev Health http://www.kidney.de/pget.php?&tw=1&pmid=34308137 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34308137 #FOAvip English Wikipedia <ref>{{Cite pmid|34308137}}</ref> Impact of smoking on COVID-19 outcomes: a HOPE Registry subanalysis #MMPMID34308137 Espejo-Paeres C; Nunez-Gil IJ; Estrada V; Fernandez-Perez C; Uribe-Heredia G; Cabre-Verdiell C; Uribarri A; Romero R; Garcia-Aguado M; Fernandez-Rozas I; Becerra-Munoz V; Pepe M; Cerrato E; Raposeiras-Roubin S; Barrionuevo-Ramos M; Aveiga-Ligua F; Aguilar-Andrea C; Alfonso-Rodriguez E; Ugo F; Garcia-Prieto JF; Feltes G; Akin I; Huang J; Jativa J; Fernandez-Ortiz A; Macaya C; Carrero-Fernandez A; Signes-Costa J BMJ Nutr Prev Health 2021[]; 4 (1): 285-292 PMID34308137show ga BACKGROUND: Smoking has been associated with poorer outcomes in relation to COVID-19. Smokers have higher risk of mortality and have a more severe clinical course. There is paucity of data available on this issue, and a definitive link between smoking and COVID-19 prognosis has yet to be established. METHODS: We included 5224 patients with COVID-19 with an available smoking history in a multicentre international registry Health Outcome Predictive Evaluation for COVID-19 (NCT04334291). Patients were included following an in-hospital admission with a COVID-19 diagnosis. We analysed the outcomes of patients with a current or prior history of smoking compared with the non-smoking group. The primary endpoint was all-cause in-hospital death. RESULTS: Finally, 5224 patients with COVID-19 with available smoking status were analysed. A total of 3983 (67.9%) patients were non-smokers, 934 (15.9%) were former smokers and 307 (5.2%) were active smokers. The median age was 66 years (IQR 52.0-77.0) and 58.6% were male. The most frequent comorbidities were hypertension (48.5%) and dyslipidaemia (33.0%). A relevant lung disease was present in 19.4%. In-hospital complications such sepsis (23.6%) and embolic events (4.3%) occurred more frequently in the smoker group (p<0.001 for both). All cause-death was higher among smokers (active or former smokers) compared with non-smokers (27.6 vs 18.4%, p<0.001). Following a multivariate analysis, current smoking was considered as an independent predictor of mortality (OR 1.77, 95% CI 1.11 to 2.82, p=0.017) and a combined endpoint of severe disease (OR 1.68, 95% CI 1.16 to 2.43, p=0.006). CONCLUSION: Smoking has a negative prognostic impact on patients hospitalised with COVID-19. äImpact of smoking on COVID-19 outcomes: a HOPE Registry subanalysis (epmc).pdf DeepDyve Pubget Overpricing